Medicines Brought to Market


MDs or PhDs on the Team


Phase 3 Success Rate*


We partner with pharmaceutical, biotech and medical technology companies to fund products that address unmet medical needs and have the potential to improve the quality of life for patients around the world.

Filling a Void

Blackstone Life Sciences (BXLS) fills a critical void in the industry. While the life sciences are seeing unprecedented innovation driven by rapid advancements in science and technology, there is a lack of funding necessary to bring medicines and healthcare technologies to market. We invest in and partner with pharmaceutical, biotechnology and medical technology companies to help meet this need.

Expertise and Scale

BXLS combines clinical, commercial and operational expertise with Blackstone’s knowledge and global network, access to capital, resources and infrastructure. We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products and companies through hands-on involvement and directly applied expertise.

Managing Risk

We seek to deliver value for investors by focusing on areas where we can apply our deep clinical and commercial domain expertise. By investing in promising candidates in late-stage development, we aim to make a positive impact on the most people with the lowest clinical risk.

Case Studies

The Blackstone Life Sciences team of employees, Senior Advisors and Development Company personnel is responsible — both in its current capacity and prior experiences— for bringing 111 medicines to market in 17 different therapeutic areas.

Note: All figures as of June 30, 2023, unless otherwise indicated.

*Medicines brought to market by BXLS and development company employees and advisors (Nick Galakatos, Emmett Cunningham, Kurt Wheeler, Barry Gertz, Dennis Henner, Ed Scolnick, Kiran Reddy, Francois Nader, Olivier Brandicourt) while they worked at prior employers. The development of a medicine involves many professionals. The degree of involvement by a given BXLS professional varies medicine to medicine. Therefore the performance shown reflects the contributions of a number of professionals and may not be indicative of any individual’s contributions to the transactions. The number of developed medicines is measured when a drug is approved in any jurisdiction. Senior Advisors are not employees of Blackstone.

Updates from Life Sciences

“We support promising companies and products, providing flexible capital and clinical expertise to advance innovation and improve outcomes for patients.”